Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
Selective inhibition of the mitochondrial permeability transition pore protects against neuro-degeneration in experimental multiple sclerosis.
4th Biannual NeuroUnit Biomarkers for Inflammation and Neurodegeneration Symposium on Biomarkers in Neurodegenerative Disease
Onset of multiple sclerosis before adulthood leads to failure of age-expected brain growth.
Genzyme’s Lemtrada Approved by the FDA
Fatal Acute Myeloid Leukemia With 11q23 MLL Gene Rearrangement Following Mitoxantrone Treatment in a Case of Childhood-onset Multiple Sclerosis.
Impact of natalizumab on ambulatory improvement in secondary progressive and disabled relapsing-remitting multiple sclerosis.
New multiple sclerosis phenotypic classification.
Novel therapies for memory cells in autoimmune diseases.
Multiple sclerosis: risk factors, prodromes, and potential causal pathways.
Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study.
Synthetic Biologics Reports Results of Independent Third Party Evaluations of Trimesta™ Data from Investigator-Sponsored Phase 2 Clinical Trial for Relapsing-Remitting Multiple Sclerosis
Rituximab, an anti-CD20 monoclonal antibody: History & mechanism: Off label rituximab use in transplant patients
[Results of a comparative clinical trial of the Russian Β - interferon-1b bioanalogue (infibeta)].
Immune response during interferon beta-1b treatment in patients with multiple sclerosis who experienced relapses and those who were relapse-free in the START study.
Pregnancy outcomes in patients exposed to interferon beta-1b.
Molecular mechanism underlying the impact of vitamin D on disease activity of MS.
IgE-Mediated Allergic Reactions after the First Administration of Glatiramer Acetate in Patients with Multiple Sclerosis.
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Natalizumab treatment during pregnancy - effects on the neonatal immune system.
New approaches in the management of multiple sclerosis.
Multiple sclerosis in children: an update on clinical diagnosis, therapeutic strategies, and research.
Genzyme presents second Phase III study of once-daily oral AUBAGIO® (teriflunomide) confirming significant impact on disability
TGFβ Signaling Regulates the Timing of CNS Myelination by Modulating Oligodendrocyte Progenitor Cell Cycle Exit through SMAD3/4/FoxO1/Sp1.
More to come: humoral immune responses in MS.

Pages